|
US4342832A
(en)
|
1979-07-05 |
1982-08-03 |
Genentech, Inc. |
Method of constructing a replicable cloning vehicle having quasi-synthetic genes
|
|
JPS5630925A
(en)
|
1979-08-21 |
1981-03-28 |
Sumitomo Chem Co Ltd |
Purification of human growth hormone
|
|
US4671958A
(en)
|
1982-03-09 |
1987-06-09 |
Cytogen Corporation |
Antibody conjugates for the delivery of compounds to target sites
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US6710169B2
(en)
|
1987-10-02 |
2004-03-23 |
Genentech, Inc. |
Adheson variants
|
|
US4952394A
(en)
|
1987-11-23 |
1990-08-28 |
Bristol-Myers Company |
Drug-monoclonal antibody conjugates
|
|
US5981485A
(en)
|
1997-07-14 |
1999-11-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
|
US5681566A
(en)
|
1988-10-24 |
1997-10-28 |
3I Research Exploitation Limited |
Antibody conjugates with two or more covalently linked FC regions
|
|
GB8824869D0
(en)
|
1988-10-24 |
1988-11-30 |
Stevenson G T |
Synthetic antibody
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CS89491A3
(en)
|
1990-04-09 |
1992-01-15 |
Chugai Pharmaceutical Co Ltd |
Hybrid calcitonin
|
|
RU2145233C1
(ru)
*
|
1990-07-02 |
2000-02-10 |
Дзе Аризона Борд оф Риджентс |
Неупорядоченная библиотека пептидов, способ ее получения и способ идентификации пептида, синтезированного твердофазным синтезом
|
|
US5506107A
(en)
|
1991-05-10 |
1996-04-09 |
Genentech, Inc. |
Selecting ligand agonists and antagonists
|
|
US6329509B1
(en)
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
|
ATE227583T1
(de)
|
1991-12-20 |
2002-11-15 |
Novo Nordisk As |
Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
ES2149768T3
(es)
|
1992-03-25 |
2000-11-16 |
Immunogen Inc |
Conjugados de agentes enlazantes de celulas derivados de cc-1065.
|
|
US5686072A
(en)
|
1992-06-17 |
1997-11-11 |
Board Of Regents, The University Of Texas |
Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5359030A
(en)
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
|
US5484892A
(en)
|
1993-05-21 |
1996-01-16 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
ATE306930T1
(de)
|
1994-08-12 |
2005-11-15 |
Immunomedics Inc |
Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5698672A
(en)
|
1995-04-04 |
1997-12-16 |
Zymogenetics, Inc. |
Synthetic calcitonin mimetics
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6103236A
(en)
|
1995-05-10 |
2000-08-15 |
Kyowa Hakko Kogyo Co., Ltd. |
Toxin conjugates
|
|
US5980895A
(en)
|
1995-10-13 |
1999-11-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
|
|
CA2249320C
(en)
|
1996-03-20 |
2008-12-23 |
Immunomedics, Inc. |
Glycosylated humanized b-cell specific antibodies
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
EP1629849B2
(en)
|
1997-01-07 |
2017-10-04 |
Amylin Pharmaceuticals, LLC |
Pharmaceutical compositions comprising exendins and agonists thereof
|
|
US6548644B1
(en)
|
1997-03-10 |
2003-04-15 |
Immunex Corporation |
Site protected protein modification
|
|
JP2002501488A
(ja)
|
1997-03-20 |
2002-01-15 |
アメリカ合衆国 |
Ｃｄ２２を保有する細胞および腫瘍へ標的化された、組換え抗体および免疫複合体
|
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
US5981488A
(en)
|
1997-03-31 |
1999-11-09 |
Eli Lillly And Company |
Glucagon-like peptide-1 analogs
|
|
EP1012184B1
(en)
|
1997-07-14 |
2007-10-10 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6576744B1
(en)
|
1998-09-23 |
2003-06-10 |
Zymogenetics, Inc. |
Cytokine receptor zalpha11
|
|
US6803451B2
(en)
|
1998-09-23 |
2004-10-12 |
Zymogenetics, Inc. |
Cytokine receptor zalpha11 polypeptides
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US7425541B2
(en)
|
1998-12-11 |
2008-09-16 |
Medarex, Inc. |
Enzyme-cleavable prodrug compounds
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
US6395226B1
(en)
|
1999-04-06 |
2002-05-28 |
Medtronic, Inc. |
Alkoxysilane/alkysilane copolymer coating of medical devices
|
|
DE19926475A1
(de)
|
1999-06-10 |
2000-12-14 |
Ktb Tumorforschungs Gmbh |
Träger-Pharmaka-Konjugate
|
|
EP1229934B1
(en)
|
1999-10-01 |
2014-03-05 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US6824780B1
(en)
|
1999-10-29 |
2004-11-30 |
Genentech, Inc. |
Anti-tumor antibody compositions and methods of use
|
|
US6897292B2
(en)
|
1999-12-03 |
2005-05-24 |
Zymogenetics, Inc. |
Human cytokine receptor
|
|
JP2004502404A
(ja)
|
2000-02-17 |
2004-01-29 |
インサイト・ゲノミックス・インコーポレイテッド |
ヒトキナーゼ
|
|
EP1263771B1
(en)
|
2000-03-16 |
2006-06-14 |
The Regents Of The University Of California |
Chemoselective ligation by use of a phosphine
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
AU2001253127A1
(en)
|
2000-04-05 |
2001-10-23 |
Zymogenetics Inc. |
Soluble zalpha11 cytokine receptors
|
|
US6756480B2
(en)
|
2000-04-27 |
2004-06-29 |
Amgen Inc. |
Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
|
|
US7214685B2
(en)
|
2000-05-02 |
2007-05-08 |
Lutz F. Tietze |
Prodrugs for a selective cancer therapy
|
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
JP2004510702A
(ja)
|
2000-06-14 |
2004-04-08 |
メダレックス，インコーポレイティド |
イソロイシンを有するプロドラッグ化合物
|
|
US7214663B2
(en)
|
2000-06-14 |
2007-05-08 |
Medarex, Inc. |
Tripeptide prodrug compounds
|
|
WO2002012345A2
(en)
|
2000-08-08 |
2002-02-14 |
Zymogenetics, Inc. |
Soluble zcytor 11 cytokine receptors
|
|
US7402556B2
(en)
|
2000-08-24 |
2008-07-22 |
Medarex, Inc. |
Prodrugs activated by plasmin and their use in cancer chemotherapy
|
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
|
AU2002213357A1
(en)
*
|
2000-10-20 |
2002-05-06 |
Idec Pharmaceuticals Corporation |
Variant igg3 rituxan r and therapeutic use thereof
|
|
ATE432986T1
(de)
|
2000-11-07 |
2009-06-15 |
Zymogenetics Inc |
Menschlicher rezeptor für tumor necrosis factor
|
|
GB0029154D0
(en)
|
2000-11-30 |
2001-01-17 |
Lee Helen |
Signal enhancement with multiple labelled-antibodies
|
|
DK1355942T3
(da)
|
2000-12-07 |
2008-11-17 |
Lilly Co Eli |
GLP-1-fusionsproteiner
|
|
JP2004532624A
(ja)
|
2001-03-02 |
2004-10-28 |
ザイモジェネティクス，インコーポレイティド |
マウスサイトカイン受容体
|
|
US6825166B2
(en)
|
2001-03-23 |
2004-11-30 |
Tapestry Pharmaceuticals, Inc. |
Molecular conjugates for use in treatment of cancer
|
|
WO2002077174A2
(en)
|
2001-03-27 |
2002-10-03 |
Zymogenetics, Inc. |
Human cytokine receptor
|
|
EP1490483B1
(en)
|
2001-04-19 |
2015-06-03 |
The Scripps Research Institute |
In vivo incorporation of unnatural amino acids
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6608196B2
(en)
|
2001-05-03 |
2003-08-19 |
Galileo Pharmaceuticals, Inc. |
Process for solid supported synthesis of pyruvate-derived compounds
|
|
US20030013846A1
(en)
|
2001-05-03 |
2003-01-16 |
Bing Wang |
Pyruvate derivatives
|
|
US20030103985A1
(en)
|
2001-05-18 |
2003-06-05 |
Boehringer Ingelheim International Gmbh |
Cytotoxic CD44 antibody immunoconjugates
|
|
US6978243B2
(en)
|
2001-05-22 |
2005-12-20 |
International Flavors & Fragrances Inc. |
Method for the analysis of sensory perception
|
|
DK1436003T3
(da)
|
2001-05-24 |
2010-03-15 |
Zymogenetics Inc |
TACI-immunoglobulin-fusionsproteiner
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US6989452B2
(en)
|
2001-05-31 |
2006-01-24 |
Medarex, Inc. |
Disulfide prodrugs and linkers and stabilizers useful therefor
|
|
JP4619651B2
(ja)
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
|
US20030109682A1
(en)
|
2001-09-07 |
2003-06-12 |
Daniel Santi |
Maytansines and maytansine conjugates
|
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
ES2342929T3
(es)
|
2001-09-26 |
2010-07-19 |
The Government of the United States of America as represented by the Secretary of Health and Human |
Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22.
|
|
US6864069B2
(en)
|
2001-10-05 |
2005-03-08 |
Bayer Pharmaceuticals Corporation |
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
|
|
ES2561985T3
(es)
|
2001-10-10 |
2016-03-01 |
Ratiopharm Gmbh |
Remodelación y glicoconjugación de anticuerpos
|
|
ATE430580T1
(de)
|
2001-10-25 |
2009-05-15 |
Genentech Inc |
Glycoprotein-zusammensetzungen
|
|
US20030171285A1
(en)
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
AU2002364586A1
(en)
|
2001-12-21 |
2003-07-30 |
Delta Biotechnology Limited |
Albumin fusion proteins
|
|
GB0130947D0
(en)
|
2001-12-24 |
2002-02-13 |
Lee Helen |
Improved sample preparation for the detection of infectious agents
|
|
CN1646161A
(zh)
|
2002-02-21 |
2005-07-27 |
杜克大学 |
自身免疫疾病的药剂和治疗方法
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
WO2003074551A2
(en)
|
2002-03-01 |
2003-09-12 |
The Administrators Of The Tulane Educational Fund |
Conjugates of therapeutic or cytotoxic agents and biologically active peptides
|
|
US20090042291A1
(en)
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20080206242A1
(en)
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
|
US20090162382A1
(en)
|
2002-03-01 |
2009-06-25 |
Bernett Matthew J |
Optimized ca9 antibodies and methods of using the same
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20100311954A1
(en)
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
|
US20080254027A1
(en)
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US20080260731A1
(en)
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US20080152649A1
(en)
|
2002-03-01 |
2008-06-26 |
Xencor, Inc. |
Optimized igf-1r antibodies and methods of using the same
|
|
US20080219974A1
(en)
|
2002-03-01 |
2008-09-11 |
Bernett Matthew J |
Optimized antibodies that target hm1.24
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
WO2003074679A2
(en)
|
2002-03-01 |
2003-09-12 |
Xencor |
Antibody optimization
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
US20070148171A1
(en)
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
JP4524181B2
(ja)
|
2002-05-30 |
2010-08-11 |
マクロジェニクス，インコーポレーテッド |
Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用
|
|
WO2003105782A2
(en)
|
2002-06-17 |
2003-12-24 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Specificity grafting of a murine antibody onto a human framework
|
|
CA2802205C
(en)
|
2002-07-31 |
2016-01-19 |
Seattle Genetics, Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
|
JP2006500364A
(ja)
|
2002-08-16 |
2006-01-05 |
イムノージェン インコーポレーテッド |
高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
|
|
US7189811B2
(en)
|
2002-09-06 |
2007-03-13 |
National Institute Of Immunology |
Process for solubilization of recombinant proteins expressed as inclusion body
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
KR20050073559A
(ko)
|
2002-10-16 |
2005-07-14 |
더 스크립스 리서치 인스티튜트 |
당단백질 합성
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
JP4773947B2
(ja)
|
2003-01-09 |
2011-09-14 |
マクロジェニクス，インコーポレーテッド |
細菌細胞及び哺乳動物細胞における抗体発現のための二重発現ベクター系
|
|
EP1587540B1
(en)
|
2003-01-09 |
2021-09-15 |
MacroGenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
|
US8227212B2
(en)
|
2003-02-11 |
2012-07-24 |
Shire Human Genetic Therapies, Inc. |
Cell that expresses a sulfatase and a formylglycine generating enzyme
|
|
WO2004073656A2
(en)
|
2003-02-20 |
2004-09-02 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US20070275460A1
(en)
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
WO2004082640A2
(en)
|
2003-03-19 |
2004-09-30 |
New Century Pharmaceuticals, Inc. |
Human serum albumin conjugates with therapeutic compounds
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
DE602004031390D1
(de)
|
2003-05-06 |
2011-03-24 |
Syntonix Pharmaceuticals Inc |
Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
|
|
US20050281829A1
(en)
|
2003-05-06 |
2005-12-22 |
Hehir Cristina A T |
Fc chimeric proteins with anti-HIV drugs
|
|
EP2281577B1
(en)
|
2003-05-14 |
2016-11-16 |
ImmunoGen, Inc. |
Drug conjugate composition
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
CA2528591C
(en)
|
2003-06-12 |
2013-01-08 |
Eli Lilly And Company |
Glp-1 analog fusion proteins
|
|
WO2005003294A2
(en)
|
2003-06-18 |
2005-01-13 |
The Scripps Research Institute |
Unnatural reactive amino acid genetic code additions
|
|
WO2005000898A2
(en)
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
|
ATE496944T1
(de)
*
|
2003-07-21 |
2011-02-15 |
Immunogen Inc |
Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
|
|
WO2005012341A2
(en)
|
2003-07-30 |
2005-02-10 |
Zymogenetics, Inc. |
Pichia methanolica secretory signal
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
JP2007507510A
(ja)
|
2003-09-30 |
2007-03-29 |
スターンベルド バイオテクノロジー ノース アメリカ， インコーポレイテッド |
トランスジェニック哺乳動物の乳汁中に外因性タンパク質を産生するためのプロセスおよびそれからタンパク質を精製するためのプロセス
|
|
ES2831379T3
(es)
|
2003-10-09 |
2021-06-08 |
Ambrx Inc |
Derivados poliméricos para la modificación selectiva de proteínas
|
|
NZ583292A
(en)
|
2003-11-06 |
2012-03-30 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
BRPI0406606A
(pt)
|
2003-11-13 |
2005-12-06 |
Hanmi Pharm Ind Co Ltd |
Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
|
|
AU2004293471C1
(en)
|
2003-11-25 |
2011-02-24 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Mutated anti-CD22 antibodies and immunoconjugates
|
|
EP1701979A2
(en)
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Optimized antibodies that target the epidermal growth factor receptor
|
|
AU2004297616B2
(en)
|
2003-12-04 |
2008-12-18 |
Xencor, Inc. |
Methods of generating variant proteins with increased host string content and compositions thereof
|
|
CN101665538A
(zh)
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
与白蛋白样物质相连的新glp-1类似物
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
WO2006069220A2
(en)
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
Modified human growth hormone
|
|
BRPI0507159A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
|
|
US7422696B2
(en)
|
2004-02-20 |
2008-09-09 |
Northwestern University |
Multicomponent nanorods
|
|
AU2005216251B2
(en)
|
2004-02-23 |
2011-03-10 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
WO2005084390A2
(en)
|
2004-03-02 |
2005-09-15 |
Seattle Genetics, Inc. |
Partially loaded antibodies and methods of their conjugation
|
|
EP2053062A1
(en)
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
|
EP1740954B1
(en)
|
2004-04-07 |
2015-08-19 |
Genentech, Inc. |
Mass spectrometry of antibody conjugates
|
|
CA2565874C
(en)
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
MXPA06013413A
(es)
|
2004-05-19 |
2007-01-23 |
Medarex Inc |
Enlazadores quimicos y conjugados de los mismos.
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
|
KR20070034512A
(ko)
|
2004-06-18 |
2007-03-28 |
암브룩스, 인코포레이티드 |
신규 항원-결합 폴리펩티드 및 이의 용도
|
|
MX2007000728A
(es)
|
2004-07-21 |
2007-03-15 |
Ambrx Inc |
Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
|
|
US7126393B2
(en)
|
2004-08-20 |
2006-10-24 |
Micron Technology, Inc. |
Delay circuit with reset-based forward path static delay
|
|
CA2579142A1
(en)
|
2004-09-13 |
2006-03-23 |
Macrogenics, Inc. |
Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
|
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
|
WO2006036834A2
(en)
*
|
2004-09-24 |
2006-04-06 |
Amgen Inc. |
MODIFIED Fc MOLECULES
|
|
AU2004324756A1
(en)
|
2004-11-09 |
2006-05-18 |
Usv Limited |
A novel process for purification of human growth harmone
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US20070135620A1
(en)
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
US7255012B2
(en)
|
2004-12-01 |
2007-08-14 |
Rosemount Inc. |
Process fluid flow device with variable orifice
|
|
GB2438982A
(en)
|
2004-12-22 |
2007-12-12 |
Ambrx Inc |
Compostions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
CA2590429C
(en)
|
2004-12-22 |
2014-10-07 |
Ambrx, Inc. |
Compositions of aminoacyl-trna synthetase and uses thereof
|
|
US8080391B2
(en)
|
2004-12-22 |
2011-12-20 |
Ambrx, Inc. |
Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
|
|
CA2594561C
(en)
|
2004-12-22 |
2014-12-23 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
|
ATE462726T1
(de)
|
2005-01-07 |
2010-04-15 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
|
US20060182750A1
(en)
|
2005-02-11 |
2006-08-17 |
Immunogen, Inc. |
Process for preparing stable drug conjugates
|
|
US7466406B2
(en)
|
2005-03-14 |
2008-12-16 |
Northwestern University |
Analyte detection using nanowires produced by on-wire lithography
|
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
WO2006133088A2
(en)
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Improved human interferon molecules and their uses
|
|
WO2006132969A2
(en)
|
2005-06-03 |
2006-12-14 |
Ambrx, Inc. |
Incorporation of non-naturally encoded amino acids into proteins
|
|
JP2007037018A
(ja)
|
2005-07-29 |
2007-02-08 |
Nec Electronics Corp |
スイッチ回路
|
|
PL1919503T3
(pl)
|
2005-08-10 |
2015-04-30 |
Macrogenics Inc |
Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
JP4829969B2
(ja)
|
2005-08-18 |
2011-12-07 |
アンブルックス，インコーポレイテッド |
ｔＲＮＡ組成物、およびその使用
|
|
CA2630415A1
(en)
|
2005-10-20 |
2007-04-26 |
The Scripps Research Institute |
Fc labeling for immunostaining and immunotargeting
|
|
EP1940789B1
(en)
|
2005-10-26 |
2011-11-23 |
Medarex, Inc. |
Methods and compounds for preparing cc-1065 analogs
|
|
WO2007056083A2
(en)
|
2005-11-02 |
2007-05-18 |
Ambrx, Inc. |
Biosynthetic polypeptide fusion inhibitors
|
|
ATE500215T1
(de)
|
2005-11-08 |
2011-03-15 |
Ambrx Inc |
Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
|
|
JP2009520949A
(ja)
|
2005-11-16 |
2009-05-28 |
アンブルックス，インコーポレイテッド |
非天然アミノ酸を含んでいる組成物および方法
|
|
EP1968635B1
(en)
|
2005-12-14 |
2014-09-17 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
CA2632832A1
(en)
|
2005-12-30 |
2007-07-12 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
CN101384711A
(zh)
|
2006-01-19 |
2009-03-11 |
Ambrx公司 |
具有经调节的免疫原性的非天然氨基酸多肽
|
|
US20070198996A1
(en)
|
2006-02-09 |
2007-08-23 |
Ziep Software Inc. |
System and method for driving peripheral devices
|
|
DE602007006429D1
(de)
|
2006-02-10 |
2010-06-24 |
Zymogenetics Inc |
Lösliches il-17rcx4 und verfahren zu dessen anwendung bei entzündungen
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
WO2007103470A2
(en)
|
2006-03-06 |
2007-09-13 |
Medimmune, Inc. |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
JP2009529331A
(ja)
|
2006-03-10 |
2009-08-20 |
マクロジェニクス，インコーポレーテッド |
変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
|
|
CA2660592C
(en)
|
2006-05-26 |
2016-07-12 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
HRP20140172T1
(hr)
|
2006-05-30 |
2014-03-28 |
Genentech, Inc. |
Protutijela i imunokonjugati kao i njihove uporabe
|
|
CN100388056C
(zh)
|
2006-06-02 |
2008-05-14 |
上海微电子装备有限公司 |
一种投影物镜光学系统
|
|
EP2505209A1
(en)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-specific antibodies and methods of the use thereof
|
|
CN101535341A
(zh)
|
2006-07-18 |
2009-09-16 |
森托科尔奥索生物科技公司 |
人glp-1模拟体、组合物、方法和用途
|
|
PT2061878E
(pt)
|
2006-09-08 |
2014-04-22 |
Ambrx Inc |
Supressor híbrido arnt para células de vertebrados
|
|
ES2465473T3
(es)
|
2006-09-08 |
2014-06-05 |
Ambrx, Inc. |
Transcripción de arnt supresor en células de vertebrado
|
|
WO2008030558A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
|
CA2662752C
(en)
|
2006-09-08 |
2016-04-12 |
Ambrx, Inc. |
Site specific incorporation of non-natural amino acids by vertebrate cells
|
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
|
US20080112961A1
(en)
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
US7476555B2
(en)
|
2006-11-15 |
2009-01-13 |
Airdio Wireless Inc. |
Method of chip manufacturing
|
|
CN103172743B
(zh)
|
2006-12-01 |
2015-04-08 |
梅达雷克斯有限责任公司 |
结合cd22的人抗体及其用途
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
WO2008077079A1
(en)
|
2006-12-18 |
2008-06-26 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
JP4467557B2
(ja)
|
2006-12-25 |
2010-05-26 |
富士通株式会社 |
光スイッチング方法及び光スイッチ
|
|
KR20090102838A
(ko)
|
2006-12-28 |
2009-09-30 |
암브룩스, 인코포레이티드 |
페나진 및 퀴녹살린 치환된 아미노산 및 폴리펩티드
|
|
US8518558B2
(en)
*
|
2007-03-29 |
2013-08-27 |
Konica Minolta Holdings, Inc. |
Organic electroluminescent element
|
|
US20080244222A1
(en)
|
2007-03-30 |
2008-10-02 |
Intel Corporation |
Many-core processing using virtual processors
|
|
JP2010523084A
(ja)
|
2007-03-30 |
2010-07-15 |
アンブルックス，インコーポレイテッド |
修飾ｆｇｆ−２１ポリペプチド
|
|
WO2008137471A2
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
|
EP3392273A1
(en)
|
2007-05-30 |
2018-10-24 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
AU2008299822A1
(en)
|
2007-06-20 |
2009-03-19 |
Northwestern University |
Universal matrix
|
|
EP3241846B1
(en)
|
2007-10-04 |
2022-02-23 |
ZymoGenetics, Inc. |
B7 family member zb7h6 and related compositions and methods
|
|
US8795667B2
(en)
|
2007-12-19 |
2014-08-05 |
Macrogenics, Inc. |
Compositions for the prevention and treatment of smallpox
|
|
US7722865B2
(en)
|
2008-01-18 |
2010-05-25 |
Biomarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
|
US8729232B2
(en)
*
|
2008-03-27 |
2014-05-20 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
|
WO2009124109A1
(en)
|
2008-04-04 |
2009-10-08 |
The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services |
Human monoclonal antibodies specific for cd22
|
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
JP2012509663A
(ja)
|
2008-11-21 |
2012-04-26 |
コーニング インコーポレイテッド |
細胞培養のための、突起間隔を開けた基板および装置
|
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
US9540438B2
(en)
|
2011-01-14 |
2017-01-10 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
|
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
|
JP6745218B2
(ja)
|
2013-11-27 |
2020-08-26 |
レッドウッド バイオサイエンス， インコーポレイテッド |
ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
|
|
KR102557615B1
(ko)
|
2014-06-06 |
2023-07-20 |
레드우드 바이오사이언스 인코포레이티드 |
항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
|